•
Mar 31, 2022

ClearPoint Neuro Q1 2022 Earnings Report

ClearPoint Neuro achieved record quarterly revenue in both Functional Neurosurgery Navigation and Biologics and Drug Delivery, with total revenue of $5.0 million, representing a 25% year-over-year growth.

Key Takeaways

ClearPoint Neuro reported a strong first quarter in 2022, achieving record revenue in both Functional Neurosurgery Navigation and Biologics and Drug Delivery, resulting in a total revenue of $5.0 million, a 25% increase year-over-year. The company is increasing its range of expected revenue for 2022 to between $21.0 and $22.0 million.

Achieved record quarterly revenue in both Functional Neurosurgery Navigation and Biologics and Drug Delivery.

Total revenue reached $5.0 million, a 25% increase year-over-year.

Biologics and Drug Delivery team added partners, bringing the total to approximately 45.

Increased the range of expected revenue for 2022 to between $21.0 and $22.0 million.

Total Revenue
$5.03M
Previous year: $4.03M
+24.8%
EPS
-$0.17
Previous year: -$0.13
+30.8%
Gross Profit
$3.25M
Previous year: $2.6M
+25.0%
Cash and Equivalents
$49.7M
Previous year: $64.9M
-23.4%
Free Cash Flow
-$4.34M
Previous year: -$2.17M
+99.8%
Total Assets
$61.8M
Previous year: $74.3M
-16.8%

ClearPoint Neuro

ClearPoint Neuro

ClearPoint Neuro Revenue by Segment

Forward Guidance

ClearPoint Neuro anticipates revenue between $21.0 and $22.0 million for 2022, which would represent between 30 – 35% growth year-over-year.